The Burden and Characteristics of Post-COVID-19 Conditions Among Laboratory-Confirmed Delta and Omicron COVID-19 Cases: A Preliminary Study From Maharashtra, India

• Published in: Curēus (Palo Alto, CA) CA), 2023-09, Vol.15 (9), p.e44888-e44888
• Main Authors: Karyakarte, Rajesh P, Das, Rashmita, Rajmane, Mansi V, Dudhate, Sonali, Agarasen, Jeanne, Pillai, Praveena, Chandankhede, Priyanka M, Labhshetwar, Rutika S, Gadiyal, Yogita, Kulkarni, Preeti P, Nizarudeen, Safanah, Mukade, Savita, Joshi, Suvarna
• Format: Article
• Language: English
• Subjects: Cardiovascular disease; COVID-19 vaccines; Epidemiology/Public Health; Genomes; Immunization; Infections; Infectious Disease; Long COVID; Medical laboratories; Pandemics; Polymerase chain reaction; Severe acute respiratory syndrome coronavirus 2
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.44888

Background: Post-COVID-19 conditions (PCC) have emerged as a significant global health concern due to their potential impact on patients’ quality of life and healthcare resources. The present study aims to understand the burden and characteristics of PCC in Maharashtra, India, and compares its prevalence among cases infected with Delta and Omicron variants.Material and methods: A retrospective observational study included 617 laboratory-confirmed Delta and Omicron variant cases. These cases were telephonically followed up to document persistent COVID-19 symptoms using a questionnaire based on the Post-COVID-19 Clinical Form from the Global COVID-19 Clinical Platform of the World Health Organization (WHO), and the results were analyzed.Results: Out of 617 laboratory-confirmed COVID-19 cases, 82.97% and 17.03% were Omicron and Delta cases, respectively. The mean follow-up period for Delta and Omicron cases was 78.05 and 21.56 weeks, respectively. A total of 40 (6.48%) cases reported persistent symptoms at follow-up, with a higher prevalence among those infected with the Delta variant (12.38%) compared to the Omicron variant (5.27%). The most common long COVID symptoms reported were malaise (25%), dyspnea (20%), post-exertional fatigue (17.5%), joint pain (15%), and frequent episodes of cough and cold (15%). Additionally, 1.94% of participants developed a new medical condition following COVID-19 infection, most commonly hypertension (25%), lung fibrosis (16.67%), and asthma (8.33%). Factors such as more than five acute symptoms, a moderate to severe disease, the need for hospitalization, and hospitalization for more than five days were significantly associated with PCC.Conclusion: Long COVID results in extended disability and illness. The varying impacts of different COVID-19 variants highlight the complex nature of post-COVID-19 complications. Our findings highlight the need for strategic planning of healthcare resources to ensure optimal response and preparedness to manage the burden of PCC.